Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
ORGANIZATION
Boehringer’s Hasson Appointed EFPIA Japan Vice Chair
The European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan said on June 22 that Marc Hasson, chairman and president of Nippon Boehringer Ingelheim, will become vice chair effective July 1. His term will run through March 2027. The appointment…
To read the full story
Related Article
- Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
- Boehringer Ingelheim Taps Marc Hasson to Lead Japan Operations
October 7, 2025
ORGANIZATION
- 60% of EFPIA Firms Could Cut Japan Trial Investments without Policy Reform
October 2, 2026
- JPMA to Complete Shift to Legal Entity on October 1
September 30, 2026
- Generic Use Rate Hits Record 90.4% in April-June: JGA
September 30, 2026
- JaDHA Calls for Digital Health Seat in Chuikyo Reform
September 28, 2026
- Digital Health Group Eager to Gain Full Seat at Chuikyo Table
September 25, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
The development of Boehringer Ingelheim’s survodutide is gathering pace, putting the GLP-1/glucagon receptor agonist in contention to become the next…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…